The Digital Backbone of Cancer Care: A New Platform Rewires the Clinic

THETFORD MINES, QC – June 18, 2026 – In the complex and often overwhelming world of oncology, the invisible infrastructure that connects patients to their care teams is as critical as the treatments themselves. A recent independent evaluation of a Quebec-based digital platform, Medherize, has provided a powerful glimpse into a future where this infrastructure is not just supportive, but intelligent. The results, released by KDA Group Inc., suggest a radical rewiring of clinical workflows that simultaneously enhances patient autonomy and alleviates the immense pressure on our healthcare systems.

Conducted at the Breast Disease Centre of CHU de Québec – Université Laval, the evaluation of Medherize offers more than just another case study for a health app. It presents a functional blueprint for a digital backbone capable of managing the intricate demands of modern cancer therapy. For the 243 breast cancer patients on complex oral treatments who participated, the platform became a central node for their care, and for the hospital, it became a powerful tool for optimization. The findings are a compelling proof-of-concept for the kind of intelligent networks that will be necessary to sustain healthcare in an era of rising chronic disease, aging populations, and persistent labor shortages.

The Anatomy of Efficiency

The core function of Medherize is to act as an intelligent triage and prioritization engine. It centralizes patient monitoring by integrating directly with the Quebec Health Record (DSQ) to pull lab results in real-time, while also capturing over 1,170 adverse effect reports directly from patients via its web and mobile application. The platform’s algorithm then sifts through this data, flagging results that require clinical intervention and automating responses where possible. This is the digital backbone in action: a system that intelligently manages information flow to direct human expertise precisely where it is most needed.

The results from the six-month evaluation are staggering. The platform achieved a near-universal 97% adoption rate among eligible patients, a remarkable figure that included a significant cohort of older users (28% were aged 70 or older). More critically, therapeutic adherence reached 93%, a substantial leap from the 70% to 90% rates typically reported for oral oncology treatments. This improved adherence had a direct clinical impact, with total treatment interruptions falling to just 17%—a fraction of the 50% rate often seen in literature. Prolonged interruptions of more than 16 days were nearly eliminated, dropping to only 4%.

For the hospital's care teams, this digital efficiency translated into a significant easing of their workload. The required pharmacist full-time equivalent was cut by 52%, and the need for medical consultations and administrative interventions plummeted by 80%. The platform’s relevance algorithm targeted the need for medical reviews with surgical precision, leading to a 91% reduction in electrocardiograms and a 60% drop in blood tests requiring manual verification. Over half of all documented treatment interruptions were managed automatically by the system, decreasing the associated clinical and administrative workload by 54%. In a healthcare system straining under the weight of rising demand—prescriptions for these specific inhibitors at CHU de Québec nearly doubled from 2023 to 2025—such gains are not just welcome; they are essential for survival.

Validating the Network

While the results are compelling, the structure of the evaluation warrants a closer look. The press release emphasizes the study's independence, conducted by the clinical team at CHU de Québec. However, the complex web of relationships in health technology development is ever-present. KDA Group made the platform available at no cost for the evaluation and paid the institution a fee to compensate for staff time, noting this contribution carried no conditions on the results. Furthermore, the platform's initial development was partly financed by pharmaceutical giants Novartis, Eli Lilly, and AstraZeneca, though this funding was separate from the evaluation itself. These financial threads, while transparently disclosed, are a standard feature of the modern health-tech landscape and a necessary context for interpreting the validation's significance.

Regardless of these connections, the platform's performance has earned it a powerful endorsement from the front lines. The clinical team that conducted the evaluation has recommended making Medherize a permanent tool for their patients. This on-the-ground validation from physicians, pharmacists, and nurses—who reported satisfaction rates of 87%, 80%, and 76% respectively—is perhaps the most crucial metric.

"These results confirm what we set out to achieve in designing the Adherize+ platform with the Medherize module: to refocus teams' attention on clinically significant situations while strengthening patient autonomy," said Jean-Marc Léveillé, President and CEO of KDA Group. "That an independent evaluation conducted in a hospital setting demonstrates this is an important validation for the future."

A Blueprint for a Scalable System

For KDA Group, a small-cap company listed on the TSX Venture Exchange (TSXV: KDA), this validation could be a pivotal moment. The company, which is currently operating at a loss with a market capitalization of around CA$17.65 million, now possesses the hard data that investors in the competitive health-tech space crave. In a market where capital is increasingly flowing towards companies with proven ROI and clear regulatory pathways, Medherize's demonstrated ability to cut costs and improve outcomes makes it a standout.

The challenge now is scalability. KDA has already planned the development of modules for other oral anticancer medications, signaling its intent to build a comprehensive platform. The potential to expand this model across Quebec and other provinces to address systemic healthcare challenges is clear. However, scaling a digital health solution is a formidable task. It requires navigating a patchwork of regulatory frameworks, both in Canada, where software like Medherize is regulated as a medical device by Health Canada, and internationally, where rules like Europe's GDPR present high barriers to entry.

KDA appears to be building a solid foundation for this expansion. The Medherize platform was designed in compliance with Quebec's stringent Law 25 for personal information protection, and its data is hosted on ISO 27001 certified servers. This built-in security and privacy infrastructure is non-negotiable for any system aspiring to become a trusted part of the global healthcare grid. The platform's successful integration with the provincial health record system also demonstrates a crucial capability for interoperability, a key hurdle for many digital health solutions.

The Human Interface of the Digital Grid

Beyond the metrics of efficiency and adherence, the evaluation reveals a fundamental improvement in the patient experience. The reported 86% patient satisfaction rate was driven by the clarity of information and the perception of a structured, reassuring follow-up process. In the often-frightening journey of cancer treatment, the feeling of being constantly and proactively monitored—without adding to the burden on clinical staff—is invaluable. By automating routine checks and empowering patients to report their own symptoms, the platform fosters a sense of agency and partnership in their own care.

This is the ultimate promise of an intelligent health network: not to replace human connection, but to fortify it. By offloading the administrative and logistical burdens that consume so much of a clinician's day, technology like Medherize frees them to focus on the complex, nuanced, and deeply human aspects of medicine. The platform's success demonstrates that a well-designed digital backbone can create a more responsive, resilient, and patient-centric healthcare system for everyone involved.